Hong Kong Stock Exchange:2197

--一项由三叶草生物和国际疫苗研究所合作进行的研究表明，与安慰剂组相比，SCB-2019（CpG 1018/铝佐剂）疫苗接种者的家庭接触者，新冠感染的可能性降低了84%-- --结果表明，通过减少家庭接触者的传播，以及之前证实的保护效力，接种SCB-2019有望帮助控制新冠在社区内的蔓延-- --SCB-2019是迄今为止在临床研究中实现前瞻性证明显著减少新冠病毒传播的疫苗之一-- 中国上海和韩国首尔, Nov. 30, 2022 (GLOBE NEWSWIRE)…

-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 -- -- New data demonstrating…

SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clover’s…

            -- 5-fold higher neutralizing antibodies against dominant Omicron BA.5 in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated vaccine compared to a third dose of…

-- Up to 12-fold higher neutralizing antibody titers observed in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated vaccine compared to a third dose of inactivated vaccine -- --…

-- 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection -- -- BA.5 neutralizing antibody levels…

-- SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) -- -- Favorable tolerability and safety profile in…

SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participantsNew positive data adds to growing body of evidence supporting potential use…

  -- Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty® (Pfizer mRNA Vaccine), and Vaxzevria® (AstraZeneca Viral Vector…

--Phase 1 clinical trial will evaluate safety and immunogenicity of several formulations of SCB-2020S as a 2-dose vaccination series in adults-- --SCB-2020S to further validate the use of Trimer-Tag™ as a plug-and-play technology…